Mario Sznol
Yale New Haven Hospital · 529 works · 69,280 citations · h-index 94
Top works
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
- Programmed death ligand-1 expression in non-small cell lung cancer
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
- Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response